AVI BioPharma to Present at ThinkEquity's Mid Year Check-Up on Healthcare Conference
June 10 2010 - 2:00PM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, announced today that the company is scheduled to
present at ThinkEquity's Mid Year Check-Up on Healthcare
Conference, June 16, 2010, at 1:00 p.m. Eastern Time in New York
City. J. David Boyle II, AVI's Interim President and Chief
Executive Officer, and Chief Financial Officer, is scheduled to
provide a company overview.
The conference presentation will be webcast live under the
events section of AVI's website at www.avibio.com, and will be
archived there following the presentation. Please connect to AVI's
website several minutes prior to the start of the broadcast to
ensure adequate time for any software download that may be
necessary.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
RNA-based therapeutics utilizing proprietary derivatives of its
antisense chemistry (morpholino-modified phosphorodiamidate
oligomers or PMOs) that can be applied to a wide range of diseases
and genetic disorders through several distinct mechanisms of
action. Unlike other RNA therapeutic approaches, AVI's antisense
technology has been used to directly target both messenger RNA
(mRNA) and its precursor (pre-mRNA), allowing for both up and
down-regulation of targeted genes and proteins. AVI's RNA-based
drug programs are being evaluated for the treatment of Duchenne
muscular dystrophy, including an ongoing systemic Phase 1b/2
clinical trial of exon skipping with AVI-4658. AVI's antiviral
programs have demonstrated promising outcomes in Ebola Zaire and
Marburg Musoke virus infections and may prove applicable to other
viral targets such as Junín, influenza, HCV or Dengue viruses. For
more information, visit www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties, including, but not limited to, the
results of research and development efforts, the results of
preclinical and clinical testing, the effect of regulation by the
FDA and other agencies, the impact of competitive products, product
development, commercialization and technological difficulties, and
other risks detailed in the company's Securities and Exchange
Commission filings.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024